Risankizumab: an approved IL-23 comparator with a long follow-up record
Risankizumab, marketed as Skyrizi and linked to the research names BI 655066 and ABBV-066, is an IL-23 antibody.
Risankizumab, marketed as Skyrizi and linked to the research names BI 655066 and ABBV-066, is an IL-23 antibody. FDA's 2024 supplemental approval letter establishes the ulcerative-colitis indication. Its prior development and use in other conditions should remain separate from the specific evidence supporting UC. FDA approval letter.
The induction study used intravenous treatment and a 12-week remission endpoint. Its companion maintenance study used subcutaneous treatment and a week-52 remission assessment, with longer follow-up retained in the registry. The induction record is completed, while the maintenance record remains active but not recruiting in the retrieved snapshot. Those different states do not imply different regulatory status for the compound. Induction, maintenance.
The published pivotal trial report provides efficacy and safety results for these defined designs. It is a more appropriate basis for an evidence comparison than the registry's recruitment label. Comparisons with mirikizumab or investigational mechanisms still require attention to prior treatment, induction response selection, remission definitions and follow-up. No head-to-head superiority conclusion is made here. Pivotal trial publication.
Longer-term follow-up can add useful information after approval, but this account does not assign a speculative next readout date. AbbVie's company resources (below) provide cash and debt context. An approved product can support a commercial business while still requiring investment and ongoing safety evaluation; corporate profitability does not settle a clinical comparison.
AbbVie — company resources
AbbVie reported $6.569 billion of cash and equivalents at June 30, $8.341 billion of current debt and $62.481 billion of long-term debt, with no short-term borrowing balance. First-half operating cash flow was $7.265 billion and net earnings $4.313 billion. Both compounds sit within a commercial portfolio that generates cash but also supports debt service, acquisitions and other development programs. Neither the cash balance nor group earnings disclose a compound-specific funding commitment. Form 10-Q filed August 3.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.